Nov 17 (Reuters) - AzurRx BioPharma Inc :
* AZURRX BIOPHARMA REQUESTS PROTOCOL AMENDMENT TO PHASE 2B OPTION 2 STUDY OF MS1819 IN CYSTIC FIBROSIS PATIENTS
* AZURRX BIOPHARMA - INTENTION IS TO IDENTIFY OPTIMAL DELIVERY METHOD AND POTENTIALLY PROVIDE ADDITIONAL SCIENTIFIC SUPPORT AND OPTIONALITY FOR MS1819
* AZURRX BIOPHARMA INC - REMAIN ON TARGET TO RELEASE TOP LINE DATA IN Q1 OF 2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.